Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme 1 selected

Guidance programme

Showing 41 to 50 of 849

TitleReference numberPublishedLast updated
Blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive minimal residual disease-negative B-cell precursor acute lymphoblastic leukaemiaTA1049
Fenfluramine for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and overTA1050
Zolbetuximab with chemotherapy for untreated claudin-18.2-positive HER2-negative unresectable advanced gastric or gastro-oesophageal junction adenocarcinomaTA1046
Atezolizumab for untreated advanced or recurrent non-small-cell lung cancer when platinum-doublet chemotherapy is unsuitable (terminated appraisal)TA1047
12 SQ-HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mitesTA1045
Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resectionTA1043
Exagamglogene autotemcel for treating severe sickle cell disease in people 12 years and overTA1044
Durvalumab with etoposide and either carboplatin or cisplatin for untreated extensive-stage small-cell lung cancerTA1041
Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancerTA1042
Ganaxolone for treating seizures caused by CDKL5 deficiency disorder in people 2 years and overTA1033

Results per page

  1. 10
  2. 25
  3. 50
  4. All